Press releaseBusiness Wire
Enanta Pharmaceuticals
ENTA · NASDAQ
$11.67+$0.26 (+2.28%)TodayMarket closed ·
Prev close $11.41
Latest news
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Participate in September Investor Conferences
- Press releaseBusiness Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
- Press releaseBusiness Wire
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
- Press releaseBusiness Wire
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
- NewsAvi Kapoor
Braze Posts Mixed Q1 Results, Joins Sidus Space, Everpure And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- News
European Medicines Agency Announces Meeting highlights From The Committee For Medicinal Products for Human Use, May 18-21
- Press releaseBusiness Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
- Press releaseBusiness Wire
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
- News
Enanta Pharma Earnings Review: Q1 Summary
- Press releaseBusiness Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
- News
Earnings Scheduled For February 9, 2026
- News
Earnings Preview For Enanta Pharma
- Press releaseBusiness Wire
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Press releaseBusiness Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
- News
Earnings Scheduled For November 17, 2025
- News
Enanta Pharma's Earnings: A Preview
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
- Press releaseBusiness Wire
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- NewsAvi Kapoor
Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Press releaseBusiness Wire
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
- Press releaseBusiness Wire
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
- NewsVandana Singh
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults
- Press releaseBusiness Wire
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
- NewsAvi Kapoor
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
- News
4 Analysts Have This To Say About Enanta Pharma
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.